The primary clinical application of Neratinib lies in its role as an extended adjuvant therapy for adult patients who have previously undergone Trastuzumab-based treatment for early-stage breast cancer characterized by HER2-positive status. This evidence concerns the gene ERBB2 and breast carcinoma.